Derek J. Royer

TL;DR: It is demonstrated that a live-attenuated HSV-1 vaccine has great translational potential and translational viability by demonstrating that, while it is comparable to a virulent parental strain in terms of immunogenicity, HSv-1 0ΔNLS does not induce significant tissue pathology.

TL;DR: Type I IFN (IFN-α/β)–driven immune responses to acute viral infection are critical to counter replication and prevent dissemination and resistance to HSV-1 in the trigeminal ganglia is conferred in part by STING and IFN- α/β signaling in both bone marrow–derived and –resident cells, which coalesce to support a robust HSV–1–specific CD8+ T cell response.

TL;DR: Allogeneic antibody responses to DR11 are comprised of all antibody isotypes at differing proportions, these combined isotypes fix complement at nominal serum concentrations, and enhancements other than the removal of IgM and IgA multimeric isotypes may be required if MFI is to be used as a means of determining anti-HLA serum antibody concentrations in diagnostic clinical assays.

TL;DR: The HSV-1 0ΔNLS vaccine is effective against ocular HSV -1 challenge, reducing ocular neovascularization and suppressing peripheral nerve virus replication in the near absence of neutralizing antibody in this unique mouse model.

TL;DR: This chapter reviews the organization and immunology of the ocular surface mucosa, common ocular pathogens, and current strategies guiding ocular vaccine development for two of the leading infectious causes of blindness worldwide: Chlamydia trachomatis and herpes simplex virus type 1.